Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.42 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24542773 | 1.00 | BRAF (0.47) | BRAFENPP2SQORIDO1TDO2 | |
| SCHEMBL24542899 | 0.91 | BRAF (0.46) | BRAFENPP2SQORIDO1TDO2 | |
| SCHEMBL30120168 | 0.89 | BRAF (0.46) | BRAFENPP2IRAK4GPR119BTK | |
| SCHEMBL26591137 | 0.89 | BRAF (0.46) | BRAFENPP2IRAK4GPR119BTK | |
| SCHEMBL29743471 | 0.89 | BRAF (0.54) | BRAFENPP2SQORIDO1TDO2 | |
| SCHEMBL24542883 | 0.89 | BRAF (0.54) | BRAFENPP2SQORIDO1TDO2 | |
| SCHEMBL29743396 | 0.89 | BRAF (0.52) | BRAFENPP2SQORIDO1TDO2 | |
| SCHEMBL26185967 | 0.89 | BRAF (0.52) | BRAFENPP2SQORIDO1TDO2 | |
| SCHEMBL30120453 | 0.89 | GPR119 (0.46) | BRAFENPP2IRAK4GPR119BTK | |
| SCHEMBL29196989 | 0.89 | GPR119 (0.46) | BRAFENPP2IRAK4GPR119BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4263518-B1 | NEW QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-12570615-B2 | Quinazolinone derivatives | HOFFMANN-LA ROCHE INC. | 2026-03-10 | — | — | US | disclosed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20230331682-A1 | NEW QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331682-A1 | NEW QUINAZOLINONE DERIVATIVES | NDUFS3, NQO2, NDUFC1 | BRAF 2269/4885ENPP2 3402/4885SQOR 88/4885 |
| US-12570615-B2 | Quinazolinone derivatives | ABL1, NQO2, CNR1 | BRAF 1372/4885ENPP2 2484/4885SQOR 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.